1270 related articles for article (PubMed ID: 28420094)
1. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
Kitade H; Chen G; Ni Y; Ota T
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094
[TBL] [Abstract][Full Text] [Related]
2. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.
Ni Y; Zhuge F; Nagashimada M; Ota T
Nutrients; 2016 Jun; 8(7):. PubMed ID: 27347998
[TBL] [Abstract][Full Text] [Related]
3. Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin.
Ota T
Adv Exp Med Biol; 2021; 1261():231-238. PubMed ID: 33783746
[TBL] [Abstract][Full Text] [Related]
4. Role of vitamin E in nonalcoholic fatty liver disease.
Nagashimada M; Ota T
IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
[TBL] [Abstract][Full Text] [Related]
5. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
6. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
8. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
Ni Y; Nagashimada M; Zhuge F; Zhan L; Nagata N; Tsutsui A; Nakanuma Y; Kaneko S; Ota T
Sci Rep; 2015 Nov; 5():17192. PubMed ID: 26603489
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
10. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
11. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
13. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
14. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
Yang T; Wang X; Jiang LF; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
[TBL] [Abstract][Full Text] [Related]
15. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression.
Miyao M; Kotani H; Ishida T; Kawai C; Manabe S; Abiru H; Tamaki K
Lab Invest; 2015 Oct; 95(10):1130-44. PubMed ID: 26214582
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
17. Rodent Models of Nonalcoholic Fatty Liver Disease.
Zhong F; Zhou X; Xu J; Gao L
Digestion; 2020; 101(5):522-535. PubMed ID: 31600750
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
20. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages.
McGettigan B; McMahan R; Orlicky D; Burchill M; Danhorn T; Francis P; Cheng LL; Golden-Mason L; Jakubzick CV; Rosen HR
Hepatology; 2019 Jul; 70(1):67-83. PubMed ID: 30516830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
